arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

UNITED THERAPEUTICS Corp

UTHR
$488.99 ▼ -8.38 (-1.68%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
72 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
87
Health
Excellent
Bullish
auto_awesome

Analytical Summary

UNITED THERAPEUTICS Corp shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $20.8B
Dividend Yield
Revenue Growth -1.9%
Op. Margin 42.2%
ROIC 4.6%
FCF / Share $4.83
Trailing P/E 62.5x
Price / Book 3.3x
FCF Yield 1.0%
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

72-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$783.30M
↓ -1.9%
Net Income Profit after all expenses
$333.00M
↑ +7.6%
Operating Margin Operating profit as % of sales
42.2%
↑ +1.3% 96th
FCF / Share Free cash flow per share
$4.83
↑ +68.1%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
96
Returns
85
Financial Health
95
Cash Quality
53

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 19 years · 72 quarters